SER190DFU

Preclinical phase

Phase i

Phase ii a

Phase ii b

Phase iii

Approved

Disease:

Diabetic Foot Ulcers

SER190 is an IL-1β receptor antagonist

SER190 is an IL-1β receptor antagonist IL-1Ra. Wound healing is a complicated well-orchestrated biological process with three phases: inflammation, proliferation and maturation.

In poorly healing diabetic wounds persistent inflammation is the dominating phase. In humans and experimental in vivo studies, predominance of pro-inflammatory cytokines such as IL-1β and TNFα are found in diabetic wounds. IL-1 participate in the pro-inflammatory positive feedback loop that sustains the pro-inflammatory macrophage phenotype seen in the poorly healing diabetic wounds.   

Targeting the IL1β pathway with SER190, an IL-1Ra in chronic diabetic wounds will be a novel approach for improving wound healing in diabetic patients.